AI assistant
Strategic Partners A/S Director's Dealing 2021
3411_rpt_2021-03-25_0a847bd0-708b-4f67-b497-2f725c67dd29.pdf
Director's Dealing
Open in viewerOpens in your device viewer
Company announcement Orphazyme A/S No. 11/2021 Ole Maaløes Vej 3
DK-2200 Copenhagen N
www.orphazyme.com Company Registration No. 32266355
Reporting of transactions in Orphazyme's shares made by persons discharging managerial responsibilities
Copenhagen, Denmark, March 25, 2021 – Pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 ("Orphazyme"), hereby notifies receipt of information of the following transactions in Orphazyme's shares by persons discharging managerial responsibilities in Orphazyme:
| 1 | Details of the Reporting Person / Closely Associated Person | ||
|---|---|---|---|
| a) | Name | Catherine Moukheibir | |
| 2 | Reason for the notification | ||
| a) | Position/status | Member of the Board of Directors | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | or auction monitor | Details of the Company, emission allowance market participant, auction platform, auctioneer | |
| a) | Name | Orphazyme A/S | |
| b) | LEI code | 54930025OZD2GGSQ7L42 | |
| 4 | conducted | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been |
|
| a) | Description of the financial instrument, type of | Shares | |
| instrument and identification code | ISIN DK0060910917 | ||
| b) | Nature of the transaction | Exercise of Restricted Share Units | |
| c) | Price(s) and volume(s) | Volume(s) Price(s) 61.1895 1,927 DKK |
|
| d) | Aggregated information | Aggregated volume: 1,927 shares | |
| Aggregated price: DKK 117,912.17 Price per share (volume weighted average): DKK 61.1895 |
|||
| e) | Date of the transaction | March 24, 2021 | |
| f) | Place of the transaction | Outside a trading venue |
| 1 | Details of the Reporting Person / Closely Associated Person | |
|---|---|---|
| a) | Name | Martijn Kleijwegt |
| 2 | Reason for the notification | |
| a) | Position/status | Member of the Board of Directors |
| b) | Initial notification/Amendment | Initial notification |
| 3 | or auction monitor | Details of the Company, emission allowance market participant, auction platform, auctioneer |
| a) | Name | Orphazyme A/S |
| b) | LEI code | 54930025OZD2GGSQ7L42 |
| 4 | conducted | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been |
| a) | Description of the financial instrument, type of instrument and identification code |
Shares ISIN DK0060910917 |
| b) | Nature of the transaction | Exercise of Restricted Share Units |
| c) | Price(s) and volume(s) | Volume(s) Price(s) 61.1895 1,927 DKK |
| d) | Aggregated information | Aggregated volume: 1,927 shares Aggregated price: DKK 117,912.17 Price per share (volume weighted average): DKK 61.1895 |
| e) | Date of the transaction | March 24, 2021 |
| f) | Place of the transaction | Outside a trading venue |
| 4 | conducted | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been |
| a) | Description of the financial instrument, type of | Shares |
| instrument and identification code | ISIN DK0060910917 | |
| b) | Nature of the transaction | Sale of shares to LSP V Cöoperatieve U.A. |
| c) | Price(s) and volume(s) | Volume(s) Price(s) - 1,927 EUR |
| d) | Aggregated information | Aggregated volume: 1,927 shares Aggregated price: EUR 1 Price per share (volume weighted average): EUR - |
| e) | Date of the transaction | March 24, 2021 |
| f) | Place of the transaction | Outside a trading venue |
| 1 | Details of the Reporting Person / Closely Associated Person | ||
|---|---|---|---|
| a) | Name | LSP V Cöoperatieve U.A. | |
| 2 | Reason for the notification | ||
| a) | Position/status | Closely Associated Person to Martijn Kleijwegt, member of the Board of Directors |
|
| b) | Initial notification/Amendment | Initial notification | |
| 3 | or auction monitor | Details of the Company, emission allowance market participant, auction platform, auctioneer | |
| a) | Name | Orphazyme A/S | |
| b) | LEI code | 54930025OZD2GGSQ7L42 | |
| 4 | conducted | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been |
|
| a) | Description of the financial instrument, type of instrument and identification code |
Shares ISIN DK0060910917 |
|
| b) | Nature of the transaction | Purchase of shares from Martijn Kleijwegt | |
| c) | Price(s) and volume(s) | Volume(s) Price(s) - 1,927 EUR |
|
| d) | Aggregated information | Aggregated volume: 1,927 shares Aggregated price: EUR 1 Price per share (volume weighted average): EUR - |
|
| e) | Date of the transaction | March 24, 2021 | |
| f) | Place of the transaction | Outside a trading venue |
For additional information, please contact
Orphazyme A/S
Anders Vadsholt, Interim CEO & CFO +45 28 98 90 55
About Orphazyme A/S
Orphazyme is a late-stage biopharmaceutical company pioneering the Heat Shock Protein response for the treatment of neurodegenerative orphan diseases. The company is harnessing amplification of Heat Shock Proteins (or HSPs) in order to develop and commercialize novel therapeutics for diseases caused by protein misfolding, protein aggregation, and lysosomal dysfunction, including lysosomal storage diseases and neuromuscular degenerative diseases. Arimoclomol, the company's lead candidate, is in clinical development for four orphan diseases: Niemann-Pick disease type C (NPC), Amyotrophic Lateral Sclerosis (ALS), Inclusion Body Myositis (IBM) and Gaucher disease. Orphazyme is headquartered in Denmark and has operations in the U.S. and Switzerland. Orphazyme's shares are listed on Nasdaq U.S. (ORPH) and Nasdaq Copenhagen (ORPHA).
About arimoclomol
Arimoclomol is an investigational drug candidate that amplifies the production of Heat Shock Proteins (HSPs). HSPs can rescue defective misfolded proteins, clear protein aggregates, and improve the function of lysosomes. Arimoclomol is administered orally and has now been studied in seven phase 1, four phase 2 and one pivotal phase 2/3 trial. Arimoclomol is in clinical development for NPC, Gaucher Disease, IBM, and ALS. Arimoclomol has received orphan drug designation (ODD) for NPC, IBM, and ALS in the US and EU. Arimoclomol has received fast-track designation (FTD) from the U.S. Food and Drug Administration (FDA) for NPC, IBM and ALS. In addition, arimoclomol has received breakthrough therapy designation (BTD) and rare-pediatric disease designation (RPDD) from the FDA for NPC.
Forward-looking statement
This company announcement may contain certain forward-looking statements, including in respect of the anticipated commercialization of arimoclomol. Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this company announcement about future events are subject to (i) change without notice and (ii) factors beyond the Company's control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as "target," "believe," "expect," "aim," "intend," "may," "anticipate," "estimate," "plan," "project," "will," "can have," "likely," "should," "would," "could", and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results, performance, or achievements to be materially different from the expected results, performance, or achievements expressed or implied by such forward-looking statements, including the risk that applicable regulatory authorities fail to approve arimoclomol on the anticipated timeline or at all. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.